DuPont Decomposition

Why does POLYMED earn its ROE?

Breaking down Return on Equity into profitability, efficiency, and leverage.

ROE = Net Margin × Asset Turnover × Equity Multiplier

10.7% = 17.7% × 0.48 × 1.26

Latest: FY2026

Profitability

Net Margin

17.7%

16.0% →17.7%

How much profit per ₹ of revenue

Efficiency

Asset Turnover

0.48x

0.67x →0.48x

Revenue per ₹ of assets

Leverage

Equity Multiplier

1.26x

1.27x →1.26x

Assets funded by equity vs debt

Trend Analysis

ROE declined by 2.8 pp over 5 years. Driven by net margin improving (16.0% → 17.7%), asset turnover declining (0.67x → 0.48x).

Historical Decomposition

Last 5 years

YearRevenuePATNet MarginAsset TOLeverageROE
FY20220Cr0Cr16.0%0.671.2713.5%
FY20230Cr0Cr16.2%0.701.2714.4%
FY20240Cr0Cr18.9%0.731.2617.6%
FY20250Cr0Cr20.3%0.521.1512.2%
FY20260Cr0Cr17.7%0.481.2610.7%

How to read DuPont

  • Rising ROE from margin = pricing power, operational improvement (good)
  • Rising ROE from turnover = better asset utilization (good)
  • Rising ROE from leverage = more debt, amplified risk (caution)
  • Falling ROE across all three = structural deterioration (red flag)

See DCF fair value for POLYMED

Combine financial quality with intrinsic value.

See Fair Value →

DuPont decomposition from audited annual financials. Factual analysis, not investment advice.

POLYMED DuPont Analysis — ROE 10.7% | YieldIQ